Sotera Health (NASDAQ:SHC) Issues FY 2025 Earnings Guidance

Key Points

• Sotera Health has issued FY 2025 earnings per share guidance between 0.750 and 0.820, exceeding the consensus estimate of 0.748.
• The company also provided revenue guidance of $1.2 billion, which is above the consensus estimate of $1.1 billion.
• Analysts have shown mixed sentiment, with Goldman Sachs upgrading Sotera Health to a "buy" rating and setting a price target of $17.00, while others have lowered their targets to $13.00.

Sotera Health (NASDAQ:SHC - Get Free Report) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of 0.750-0.820 for the period, compared to the consensus estimate of 0.748. The company issued revenue guidance of $1.2 billion-$1.2 billion, compared to the consensus revenue estimate of $1.1 billion.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Sotera Health from a "hold" rating to a "buy" rating in a report on Saturday, June 28th. Barclays reiterated an "overweight" rating on shares of Sotera Health in a report on Friday. The Goldman Sachs Group raised shares of Sotera Health from a "neutral" rating to a "buy" rating and increased their price objective for the company from $14.00 to $17.00 in a research note on Monday, May 5th. Finally, Piper Sandler lowered their price objective on shares of Sotera Health from $15.00 to $13.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $16.00.

Sotera Health Price Performance

NASDAQ SHC traded up $0.72 during trading hours on Tuesday, reaching $14.78. The company's stock had a trading volume of 1,215,668 shares, compared to its average volume of 1,210,276. The stock has a market cap of $4.20 billion, a PE ratio of 184.37 and a beta of 1.81. Sotera Health has a fifty-two week low of $9.53 and a fifty-two week high of $17.08. The company's 50-day moving average is $11.67 and its two-hundred day moving average is $12.02. The company has a debt-to-equity ratio of 4.31, a quick ratio of 2.23 and a current ratio of 2.47.

Sotera Health (NASDAQ:SHC - Get Free Report) last released its quarterly earnings results on Friday, August 8th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.03. Sotera Health had a net margin of 2.14% and a return on equity of 39.42%. The company had revenue of $294.34 million for the quarter, compared to analysts' expectations of $275.81 million. During the same period last year, the company earned $0.19 EPS. The firm's revenue for the quarter was up 6.4% compared to the same quarter last year. Analysts forecast that Sotera Health will post 0.61 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Creative Planning increased its stake in shares of Sotera Health by 15.3% in the second quarter. Creative Planning now owns 20,186 shares of the company's stock worth $224,000 after buying an additional 2,673 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Sotera Health by 125.5% in the first quarter. Acadian Asset Management LLC now owns 25,192 shares of the company's stock worth $293,000 after buying an additional 14,018 shares during the last quarter. Empowered Funds LLC increased its stake in shares of Sotera Health by 11.1% in the first quarter. Empowered Funds LLC now owns 28,512 shares of the company's stock worth $332,000 after buying an additional 2,845 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Sotera Health by 14.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 342,934 shares of the company's stock worth $3,999,000 after buying an additional 43,471 shares during the last quarter. 91.03% of the stock is owned by institutional investors and hedge funds.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.